Clinical Trials /

First-in-human Study of CA102N Monotherapy and of CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors

NCT03616574

Description:

Study HS-CA102N-101 is a phase 1, two part (dose escalation, dose expansion), multicenter, non-randomized, open-label, multiple dose, first-in-human study of CA102N monotherapy and of CA102N combined with trifluridine/tipiracil (LONSURF) in subjects with advanced solid tumors. CA102N will be evaluated in subjects with locally advanced or metastatic solid tumours for which no effective therapy is available in Part 1 (dose escalation) and in subjects with relapsed or refractory locally advanced or metastatic colorectal cancer (mCRC) after prior oxaliplatin and irinotecan-based chemotherapy in Part 2 (dose expansion).

Related Conditions:
  • Malignant Solid Tumor
Recruiting Status:

Recruiting

Phase:

Phase 1

Trial Eligibility

Document

Title

  • Brief Title: First-in-human Study of CA102N Monotherapy and of CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors
  • Official Title: Phase 1, Two-part (Dose Escalation, Dose Expansion), Multicenter, Non-randomized, Open-label, Multiple Dose, First-in-human Study of CA102N Monotherapy and of CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors

Clinical Trial IDs

  • ORG STUDY ID: HS-CA102N-101
  • NCT ID: NCT03616574

Conditions

  • Advanced or Metastatic Solid Tumors
  • Advanced or Metastatic Colorectal Cancer (mCRC)

Interventions

DrugSynonymsArms
CA102NNim-HA ConjugateDose Escalation - CA102N Monotherapy
LONSURFTrifluridine/TipiracilDose Escalation - CA102N plus LONSURF

Purpose

Study HS-CA102N-101 is a phase 1, two part (dose escalation, dose expansion), multicenter, non-randomized, open-label, multiple dose, first-in-human study of CA102N monotherapy and of CA102N combined with trifluridine/tipiracil (LONSURF) in subjects with advanced solid tumors. CA102N will be evaluated in subjects with locally advanced or metastatic solid tumours for which no effective therapy is available in Part 1 (dose escalation) and in subjects with relapsed or refractory locally advanced or metastatic colorectal cancer (mCRC) after prior oxaliplatin and irinotecan-based chemotherapy in Part 2 (dose expansion).

Detailed Description

      Study HS-CA102N-101 is a phase 1, two part (dose escalation, dose expansion), multicenter,
      non-randomized, open-label, multiple dose, first-in-human study of CA102N monotherapy and of
      CA102N combined with trifluridine/tipiracil (LONSURF) in subjects with advanced solid tumors.

      Part 1 (dose escalation) will determine the safety and tolerability of three dose levels of
      CA102N as monotherapy and the safety, tolerability and preliminary recommended phase 2 dose
      (RP2D) of CA102N in combination with trifluridine/tipiracil (LONSURF) in patients with
      locally advanced or metastatic solid tumors.

      Part 2 (dose expansion) will further investigate the safety and tolerability of the
      combination of CA102N and trifluridine/tipiracil (LONSURF) at the preliminary RP2D in
      patients with locally advanced or metastatic colorectal cancer that has relapsed after or is
      refractory to oxaliplatin and irinotecan-based chemotherapy, an anti-vascular endothelial
      growth factor (VEGF) biological therapy, and if RAS wild-type metastatic colorectal cancer,
      an anti-epidermal growth factor receptor (EGFR) therapy..

      Preliminary efficacy will be evaluated in Parts 1 and 2 of the study as an exploratory
      endpoint.
    

Trial Arms

NameTypeDescriptionInterventions
Dose Escalation - CA102N MonotherapyExperimental0.36, 0.54, and 0.72 mg/kg of nimesulide equivalents of CA102N on Days 1 and 15 of a 28-day cycle
  • CA102N
Dose Escalation - CA102N plus LONSURFExperimental0.36, 0.54, and 0.72 mg/kg of nimesulide equivalents of CA102N on Days 1 and 15 in combination with 35 mg/m2/dose of LONSURF orally twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle
  • CA102N
  • LONSURF
Dose Expansion - CA102N plus LONSURFExperimentalThe preliminary RP2D of CA102N on Days 1 and 15 in combination with 35 mg/m2/dose of LONSURF orally twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle
  • CA102N
  • LONSURF

Eligibility Criteria

        Inclusion Criteria:

          -  Subjects enrolled in Part 1 must have histologically documented locally advanced or
             metastatic solid tumor for which there is no effective therapy available.

          -  Subjects enrolled in Part 2 must have histologically documented locally advanced or
             metastatic colorectal cancer that has relapsed after or is refractory to oxaliplatin
             and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS
             wild-type, an anti-EGFR therapy.

          -  Age ≥18 years (US) or ≥20 years (Taiwan).

          -  ECOG performance status 0-1.

          -  Measurable or non-measurable disease based on RECIST version 1.1. Subjects enrolled in
             Part 2 must have at least one measurable lesion.

          -  Adequate organ function within 14 days before 1st dose of study drug, defined as:

               1. Platelet count ≥ 100,000/mm3.

               2. Hemoglobin ≥ 9.0 g/dL.

               3. Absolute neutrophil count ≥ 1500/mm3 (without hematopoietic growth factor
                  support).

               4. Creatinine ≤ 1.5 x ULN, or creatinine clearance ≥ 50 mL/min as calculated using
                  the modified Cockcroft-Gault equation.

               5. Aspartate aminotransferase: (i) ≤3 x ULN in subjects without liver metastasis or
                  ≤5 x ULN in subjects with liver metastasis in CA102N monotherapy treatment group;
                  (ii) ≤3 x ULN in subjects who will be treated with CA102N combined with
                  trifluridine/tipiracil (LONSURF).

               6. Alanine aminotransferase: (i) ≤3 x ULN in subjects without liver metastasis or ≤5
                  x ULN in subjects with liver metastasis in CA102N monotherapy treatment group;
                  (ii) ≤3 x ULN in subjects who will be treated with CA102N combined with
                  trifluridine/tipiracil (LONSURF).

               7. Total bilirubin ≤1.5 x ULN (unless documented Gilbert's Syndrome).

          -  Has had an adequate treatment washout period prior to 1st dose of study drug defined
             as:

               1. No major surgery within the past 4 weeks.

               2. No extended field radiation therapy within the prior 4 weeks.

               3. No anticancer therapy or bevacizumab within the prior 3 weeks.

               4. No investigational agent received within prior 4 weeks (or 5 times the half-life
                  of the investigational agent, whichever is shorter).

               5. No aspirin or NSAIDs for at least 72 hours before 1st dose of study drug.

               6. No herbal supplements taken as anticancer agents within the prior 7 days.

          -  Able to provide written informed consent.

          -  Life expectancy of ≥ 3 months.

          -  Women of childbearing potential and men with partners of childbearing potential must
             agree to use a highly effective means of contraception from study entry through at
             least 6 months after the last dose of CA102N. Women of childbearing potential are
             those women who have not been permanently sterilized or are not postmenopausal.

        Exclusion Criteria:

          -  For Part 2, active malignancies other than colorectal cancer.

          -  History of hypersensitivity or hepatotoxic reaction to nimesulide or to any excipient.

          -  Requiring therapeutic doses of anticoagulants.

          -  History or presence of a bleeding tendency or disorder.

          -  History of gastrointestinal bleed or perforation related to previous NSAID therapy.

          -  Presence or history of recurrent peptic ulcer or hemorrhage.

          -  History of cerebrovascular or other active bleeding.

          -  Myocardial infarction within the last 12 months, severe or unstable angina,
             symptomatic congestive heart failure New York Heart Association (NYHA) Class III or
             IV.

          -  History of a serious cardiac arrhythmia requiring treatment.

          -  Corrected QT prolongation using Fridericia formula (QTcF), of > 450 msec for males or
             > 470 msec for females based on a triplicate 12-lead ECG.

          -  Clinically significant lung disease (eg, interstitial pneumonia, interstitial lung
             disease, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) requiring
             continuous systemic corticosteroid treatment for 6 months before registration or who
             are suspected to have such diseases by imaging at Screening.

          -  Ascites, pleural effusion, or pericardial fluid requiring drainage in last 4 weeks.

          -  Active autoimmune disease that has required systemic treatment in past 2 years.

          -  History of allogeneic transplantation requiring immunosuppressive therapy.

          -  Known positive test for hepatitis B (HBV), hepatitis C (HCV) or human immunodeficiency
             virus (HIV).

          -  Clinically active brain metastases, defined as untreated and symptomatic, or requiring
             therapy with steroids or anticonvulsants to control associated symptoms.

          -  Pregnant or breast feeding.

          -  Unresolved toxicity of greater than or equal to NCI-CTCAE (version 5.0) Grade 2
             attributed to any prior therapies (excluding anemia, alopecia, skin pigmentation, and
             platinum-induced neurotoxicity).

          -  Concomitant medical condition that would increase the risk of toxicity, in the opinion
             of the Investigator.
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Number of subjects with treatment-related adverse events as assessed by NCI-CTCAE v5.0
Time Frame:The safety measures will be assessed and recorded throughout the trial until 30 days following treatment termination (an average of 1 year).
Safety Issue:
Description:The primary endpoint for the study is the safety and tolerability of CA102N monotherapy and CA102N combined with trifluridine/tipiracil (LONSURF) as determined according to the NCI-CTCAE version 5.0.

Secondary Outcome Measures

Measure:Serum concentration of CA102N
Time Frame:Serum sampling timepoints: predose, 0.5,1, 2, 4, 8, 12, 24, 48, and 72 hours postdose CA102N on Days 1 and 15 at Cycle 1 (each cycle is 28 days).
Safety Issue:
Description:The secondary endpoint of the study is to measure serum concentration of CA102N (ng/mL).

Details

Phase:Phase 1
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Holy Stone Healthcare Co., Ltd

Last Updated

June 25, 2019